


## Financial Overview as at 30th November 2007


### Income and Expenditure

**I&E Position 2007/08**



### Balance Sheet

**Capital Programme**



### RISKS


- Delivery of SLA Activity ●
- Management of Waiting list initiative costs ●
- Utilisation of Investment fund ●
- Management of emerging cost pressures ●
- Forecasting cost consequences of 'NICE' drugs ●
- Recruitment to vacant posts ●

	Plan	Actual	Variance
	£ms	£ms	£ms
<b>Month 8</b>			
EBITDA	38.3	39.3	1.1
Operating Surplus	23.7	24.3	0.6
I&E Surplus £ms	16.3	17.8	1.5
<b>Margins</b>			
	%	%	%
EBITDA Margin	9.3	9.3	0.0
Operating Margin	5.8	5.8	0.0

Liquidity		Risk
	£ms	
Cash	57.0	●
Debtor Days	8.7	●
Current Ratio (Liquidity)	1.6	●
Working Capital Facility	50.0	●
Prudential Borrowing Limit	129.1	●
BPPC	93.15%	●

<b>Financial Risk Rating</b>	<b>4.8</b>
------------------------------	------------

### Risk Rating Explanations



Underlying Performance	Weighting	Actual	Rating
EBITDA Margin	25%	9.3%	4
<b>Achievement of Plan</b>			
EBITDA Achieved	10%	102.7%	5
<b>Financial Efficiency</b>			
Return on assets excluding dividend	20.0%	10.1%	5
I&E Surplus Margin net of dividend	20.0%	4.2%	5
<b>Liquidity</b>			
Liquidity Ratio (days)	25%	62	5

- Actual EBITDA divided by Income for the period
- Actual EBITDA divided by Planned EBITDA
- Surplus + dividend + impairments divided by average net assets
- Surplus + impairment divided by income for the period
- Cash plus debtors plus unused working capital facility minus creditors and accruals expressed in number of days operating expenses that could be covered